1. CRISPR-Cas9 system: a novel and promising era of genotherapy for beta-hemoglobinopathies, hematological malignancy, and hemophilia

   • Abdulfatah M. Alayoubi
   • Zakaria Y. Khawaji
   • François E. Mercier

   Review Article 22 September 2023 Pages: 1805 - 1817

   

2. Coagulation and Inflammation in COVID-19: Reciprocal Relationship between Inflammatory and Coagulation Markers

   • Rasoul Ebrahimi
   • Fatemeh Nasri
   • Tahereh Kalantari

   Review Article 13 February 2024 Pages: 1819 - 1831

3. Therapeutic progress in relapsed/refractory multiple myeloma

   • Qi Chen
   • Min Zhang
   • Yamin Tan

   Review Article 13 April 2024 Pages: 1833 - 1841

4. Recent progress in chimeric antigen receptor therapy for acute myeloid leukemia

   • Xiangyu Wang
   • Yanming Zhang
   • Shengli Xue

   Review Article 21 February 2024 Pages: 1843 - 1857

   

5. Waldenström macroglobulinemia: a review of pathogenesis, current treatment, and future prospects

   • Bushra Ghafoor
   • Shameera Shaik Masthan
   • Faiz Anwer

   Review Article 06 July 2023 Pages: 1859 - 1876

6. A nomogram model for predicting the efficacy of cyclosporine in patients with pure red cell aplasia

   • Liyan Yang
   • Haiyue Niu
   • Rong Fu

   Original Article 03 February 2024 Pages: 1877 - 1885

   

7. Impact of genotype on multi-organ iron and complications in patients with non-transfusion-dependent β-thalassemia intermedia

   • Antonella Meloni
   • Laura Pistoia
   • Filippo Cademartiri

   Original Article 06 April 2024 Pages: 1887 - 1896

8. Comparison of human leukocyte antigen in patients with paroxysmal nocturnal hemoglobinuria of different clone sizes

   • Zhuxin Zhang
   • Qinglin Hu
   • Bing Han

   Original Article 15 April 2024 Pages: 1897 - 1907

   

9. Expert consensus on the management of infusion-related reactions (IRRs) in patients with sickle cell disease (SCD) receiving crizanlizumab: a RAND/UCLA modified Delphi panel

   • Julie Kanter
   • Kenneth I. Ataga
   • Michael S. Broder

   Original Article 20 April 2024 Pages: 1909 - 1917

   

10. Inhibition of NRF2 signaling overcomes acquired resistance to arsenic trioxide in FLT3-mutated Acute Myeloid Leukemia

    • Daniel Zechariah Paul Jebanesan
    • Raveen Stephen Stallon Illangeswaran
    • Poonkuzhali Balasubramanian

    Original Article 17 April 2024 Pages: 1919 - 1929

    

11. Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the “RAMP” Italian multicenter prospective study

    • F. Palandri
    • G. Auteri
    • G. A. Palumbo

    Research Open access 13 March 2024 Pages: 1931 - 1940

    

12. Incidence of pleural effusion with dasatinib and the effect of switching therapy to a different TKI in patients with chronic phase CML

    • Akriti G Jain
    • Quinto Gesiotto
    • Kendra Sweet

    Research Open access 18 April 2024 Pages: 1941 - 1945

    

13. Association of JAK2V617F allele burden and clinical correlates in polycythemia vera: a systematic review and meta-analysis

    • Chih-Cheng Chen
    • Justin L. Chen
    • Hsin-An Hou

    Research Open access 23 April 2024 Pages: 1947 - 1965

    

14. GLI1 polymorphisms influence remission rate and prognosis of young de novo acute myeloid leukemia patients treated with cytarabine-based chemotherapy

    • Yanfeng Liu
    • Yi Liu
    • Xiaoping Chen

    Research 27 April 2024 Pages: 1967 - 1977

    

15. 1q21+ is associated with poor prognosis in newly diagnosed multiple myeloma patients with extramedullary disease: a retrospective study

    • Shuang Gao
    • Fei Dong
    • Hongmei Jing

    Original Article 11 January 2024 Pages: 1979 - 1987

    

16. Immune profiling of patients with extranodal natural killer/T cell lymphoma treated with daratumumab

    • Min Qing
    • Tianyuan Zhou
    • Raluca I. Verona

    Original Article Open access 18 January 2024 Pages: 1989 - 2001

    

17. Modified R-BAC plus BTK inhibitor regimen in newly diagnosed young patients with mantle cell lymphoma: a real-world retrospective study

    • Wenqi Li
    • Yu Chang
    • Lei Zhang

    Original Article 03 February 2024 Pages: 2003 - 2012

    

18. Low incidence of tumor lysis syndrome in elderly patients with chronic lymphocytic leukemia treated with venetoclax under real-world conditions: results from the prospective observational VeRVe study

    • Ingo Schwaner
    • Thomas Kuhn
    • Davide Rossi

    Original Article Open access 29 February 2024 Pages: 2013 - 2020

19. Secondary central nervous system involvement in patients with diffuse large B-cell lymphoma treated with rituximab combined CHOP therapy – a supplementary analysis of JCOG0601

    • Kazuyuki Shimada
    • Ken Ohmachi
    • Hirokazu Nagai

    Original Article Open access 27 January 2024 Pages: 2021 - 2031

    

20. Patterns and prognostic impact of CNS infiltration in adults with newly diagnosed acute lymphoblastic leukemia

    • Luiza Lapolla Perruso
    • Elvira Velloso
    • Wellington Fernandes Silva

    Original Article 05 January 2024 Pages: 2033 - 2039

    

21. Nomogram for predicting survival of patients with diffuse large B-cell lymphoma

    • Keiichiro Fujii
    • Atsushi Inagaki
    • Hiroshi Inagaki

    Original Article 27 February 2024 Pages: 2041 - 2050

    

22. Comparable outcomes of allogeneic peripheral blood versus bone marrow hematopoietic stem cell transplantation from a sibling donor for pediatric patients

    • Bo Kyung Kim
    • Kyung Taek Hong
    • Hyoung Jin Kang

    Original Article Open access 10 April 2024 Pages: 2051 - 2058

    

23. Systemic inflammatory autoimmune disease before allogeneic hematopoietic stem cell transplantation is a risk factor for death in patients with myelodysplastic syndrome or chronic myelomonocytic leukemia

    • Kumiyo Tazoe
    • Naonori Harada
    • Hirohisa Nakamae

    Original Article 25 April 2024 Pages: 2059 - 2072

    

24. Efficacy and prognostic factors of allogeneic hematopoietic stem cell transplantation treatment for adolescent and adult Tlymphoblastic leukemia /lymphoma: a large cohort multicenter study in China

    • Lan Luo
    • Yang Jiao
    • Hongmei Jing

    Research 06 April 2024 Pages: 2073 - 2087

    

25. Combining serum microRNAs and machine learning algorithms for diagnosing infectious fever after HSCT

    • Wenwei Shao
    • Yixuan Wang
    • Xiaolei Pei

    Research 01 May 2024 Pages: 2089 - 2102

    

26. Unrelated umbilical cord blood transplantation with low-dose anti-thymocyte globulin for children with severe aplastic anemia: A case series

    • Mengze Hu
    • Junhui Li
    • Litian Xuan

    Research 24 April 2024 Pages: 2103 - 2111

    

27. Quality of life after immune suppressive therapy in aplastic anemia

    • Iris N. Lommerse
    • Chris Hinnen
    • Jennifer M.-L. Tjon

    Original Article Open access 05 April 2024 Pages: 2113 - 2121

    

28. Efficacy and safety of tixagevimab/cilgavimab as passive immunisation against COVID-19 infections in patients with hematological malignancies

    • Patrick Reimann
    • Verena Petzer
    • Magdalena Anna Benda

    Research 02 March 2024 Pages: 2123 - 2131

    

29. Pharmacogenetic guided versus standard warfarin dosing for routine clinical care with its pharmacoeconomic impact: a randomized controlled clinical trial

    • Aishwarya Anand
    • Naveen C Hegde
    • Samir Malhotra

    Research 18 April 2024 Pages: 2133 - 2144

    

30. Analysis of four hereditary protein C deficiencies associated with vascular thromboembolism

    • Xuanyu Chen
    • Chengxiang Yuan
    • Ming Zou

    Research 04 March 2024 Pages: 2145 - 2155

    

31. Triple a score (AAA: age, absolute neutrophil count and absolute lymphocyte count) and its prognostic utility in patients with overt fibrotic and prefibrotic myelofibrosis

    • Marko Lucijanic
    • Ivan Krecak
    • Rajko Kusec

    Correspondence 23 April 2024 Pages: 2157 - 2159

    

32. Cerebral infarction in a patient with inhibitor-positive hemophilia B treated with plasma-derived factor VIIa and factor X mixture

    • Katsuyoshi Shimozawa
    • Hiroshi Yagasaki
    • Ichiro Morioka

    Correspondence 13 April 2024 Pages: 2161 - 2162

    

33. Letter to Editor: Treatment with the apoptosis inhibitor asunercept reduces clone sizes in patients with lower risk myelodysplastic neoplasms

    • Syeda Dua e Zehra Zaidi
    • Syeda Mahrukh Fatima Zaidi
    • Burhanuddin Sohail Rangwala

    Correspondence 23 April 2024 Pages: 2163 - 2164

34. Thiotepa-busulfan-fludarabine-based conditioning as a promising approach prior to allogeneic hematopoietic stem cell transplantation in patients with blastic plasmacytoid dendritic cell neoplasm

    • Xianbo Huang
    • Shasha Wang
    • Jiejing Qian

    Case Report 08 April 2024 Pages: 2165 - 2168

    

35. Could it be VEXAS?

    • Hippolyte Guerineau
    • Milena Kohn
    • Aurélie Cabannes-Hamy

    Case Report 09 April 2024 Pages: 2169 - 2171

    

36. Diagnosing aceruloplasminemia: navigating through red herrings

    • Zeni Kharel
    • Himal Kharel
    • Pradyumna D. Phatak

    Case Report 19 April 2024 Pages: 2173 - 2176

37. Systematic analysis of copper, zinc, and selenium levels in JAK2 V617F-positive myeloproliferative neoplasms

    • Velizar Shivarov
    • Gergana Tsvetkova
    • Milena Ivanova

    Letter to the Editor 17 January 2024 Pages: 2177 - 2179

    

38. Cystatin F a potential diagnostic biomarker in acute promyelocytic leukemia

    • Hamenth Kumar Palani
    • Saravanan Ganesan
    • Vikram Mathews

    Letter to the Editor 01 March 2024 Pages: 2181 - 2183